occurred in the first 8 days (range: 1 to 19) of a treatment cycle, however, cases have also been reported on other days throughout the cycle. the median time to resolution of cls was 12 days (range: 1 to 53). monitor patient weight and blood pressure prior to each lumoxiti infusion and as clinically indicated during treatment. assess patients for signs and symptoms of cls, including weight gain (increase in 5.5 pounds (2.5 kg) or ≥ 5% from day 1 of current cycle), hypotension, peripheral edema, shortness of breath or cough, and pulmonary edema and/or serosal effusions. in addition, the following changes in laboratory parameters may help identify cls: hypoalbuminemia, elevated hematocrit, leukocytosis, and thrombocytosis [see dosage and administration (2.3) ] . cls may be life-threatening or fatal if treatment is delayed. counsel patients to seek immediate medical attention should signs or symptoms of cls occur at any time. patients who develop cls should receive appropriate supportive measures, including concomitant oral or intravenous corticosteroids, and hospitalization as clinically indicated. withhold lumoxiti for grade 2 cls until resolution, and permanently discontinue for grade ≥ 3 cls [see dosage and administration (2.3) ] . 5.2 hemolytic uremic syndrome (hus) hemolytic uremic syndrome (hus), including life threatening cases, has been reported in patients treated with lumoxiti and is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and progressive renal failure. in the combined safety database of hcl patients treated with lumoxiti, hus occurred in 7% (9/129) of patients, including grade 3 in 3% (4/129) and grade 4 in 0.8% (1/129). most cases of hus occurred in the first 9 days (range: 1 to 16) of a treatment cycle, however, cases have also been reported on other days throughout the cycle. the median time to resolution of hus was 11.5 days (range: 2 to 44). all cases resolved, including those who discontinued lumoxiti. avoid lumoxiti in patients with prior history of severe thrombotic microangiopathy (tma) or hus. administer prophylactic intravenous fluids before and after lumoxiti infusions [see dosage and administration (2.2) ]. in study 1053, patients with a platelet count ≥ 100,000/mm 3 received low-dose aspirin on days 1 through 8 of each 28-day cycle for prophylaxis of thrombosis. monitor blood chemistry and complete blood counts prior to each dose and on day 8 of each treatment cycle. monitoring mid-cycle is also recommended. consider the diagnosis of hus in patients who develop hemolytic anemia, worsening or sudden onset of thrombocytopenia, increase in creatinine levels, elevation of bilirubin and/or ldh, and have evidence of hemolysis based on peripheral blood smear schistocytes [see dosage and administration (2.3) ] . the events of hus may be life-threatening if treatment is delayed with increased risk of progressive renal failure requiring dialysis. if hus is suspected initiate appropriate supportive measures, including fluid repletion, hemodynamic monitoring, and consider hospitalization as clinically indicated. discontinue lumoxiti in patients with hus [see dosage and administration (2.3) ] . 5.3 renal toxicity renal toxicity has been reported in patients treated with lumoxiti therapy. in the combined safety database of hcl patients treated with lumoxiti, 26% (34/129) reported adverse events of renal toxicity, including acute kidney injury (2.3%), renal failure (2.3%), renal impairment (1.6%), serum creatinine increased (17%), and proteinuria (8%). grade 3 acute kidney injury occurred in 1.6% (2/129) of patients. all other events were mild to moderate in severity. based on laboratory findings, during treatment, serum creatinine increased by two or more grades from baseline in 22% (29/129) of patients, including increases of grade 3 in 1.6% (2/129) of patients. at the end of treatment, serum creatinine levels remained elevated at 1.5- to 3-times the upper limit of normal in 5% of patients. patients who experience hus, those ≥ 65 years of age, or those with baseline renal impairment may be at increased risk for worsening of renal function following treatment with lumoxiti [see use in specific populations (8.5) ] . monitor renal function prior to each infusion of lumoxiti, and as clinically indicated throughout treatment. delay lumoxiti dosing in patients with grade ≥ 3 elevations in creatinine, or upon worsening from baseline by ≥ 2 grades [see dosage and administration (2.3) ] . 5.4 infusion related reactions infusion related reactions occurred in patients treated with lumoxiti, and were defined as the occurrence of any one of the following events on the day of study drug infusion: chills, cough, dizziness, dyspnea, feeling hot, flushing, headache, hypertension, hypotension, infusion related reaction, myalgia nausea, pyrexia, sinus tachycardia, tachycardia, vomiting, or wheezing. in study 1053, infusion related reactions occurred in 50% (40/80) of patients. grade 3 infusion related events as defined, occurred in 3.8% (3/80) of lumoxiti-treated patients. the most frequently reported infusion related events were nausea (15%), pyrexia (14%), chills (14%), vomiting (11%), headache (9%), and infusion related reaction (9%). infusion related reactions may occur during any cycle of treatment with lumoxiti. prior to each dose of lumoxiti, premedicate with antihistamines and antipyretics. if a severe infusion related reaction occurs, interrupt the lumoxiti infusion and institute appropriate medical management. administer an oral or intravenous corticosteroid approximately 30 minutes before resuming, or before the next lumoxiti infusion [see dosage and administration (2.2) ] . 5.5 electrolyte abnormalities in the combined safety database of hcl patients treated with lumoxiti, electrolyte abnormalities occurred in 57% (73/129) of patients with the most common electrolyte abnormality being hypocalcemia occurring in 25% of patients. grade 3 electrolyte abnormalities occurred in 14% (18/129) of patients and grade 4 electrolyte abnormalities occurred in 0.8% (1/129) of patients. electrolyte abnormalities co-occurred in the same treatment cycle with cls, hus, fluid retention, or renal toxicity in 37% (48/129) of patients. monitor serum electrolytes prior to each dose and on day 8 of each treatment cycle. monitoring mid-cycle is also recommended.

0.9% sodium chloride injection, usp) over 2‑4 hours before and after each lumoxiti infusion. administer 0.5 l to patients under 50 kg. advise all patients to adequately hydrate with up to 3 l (twelve 8‑oz glasses) of oral fluids (e.g., water, milk, or juice) per 24 hours on days 1 through 8 of each 28‑day cycle. in patients under 50 kg, up to 2 l (eight 8‑oz glasses) per 24 hours is recommended. monitor fluid balance and serum electrolytes to avoid fluid overload and/or electrolyte abnormalities [see warnings and precautions (5.2 , 5.5) ] . thromboprophylaxis consider low-dose aspirin on days 1 through 8 of each 28-day cycle. monitor for signs and symptoms of thrombosis [see warnings and precautions (5.2) ] . premedication premedicate 30‑90 minutes prior to each lumoxiti infusion with: • an antihistamine (e.g., hydroxyzine or diphenhydramine) • acetaminophen antipyretic • a histamine‑2 receptor antagonist (e.g., ranitidine, famotidine, or cimetidine) if a severe infusion related reaction occurs, interrupt the lumoxiti infusion and institute appropriate medical management. administer an oral or intravenous corticosteroid approximately 30 minutes before resuming, and before each lumoxiti infusion thereafter [see warnings and precautions (5.4) ] . post-infusion medication • consider oral antihistamines and antipyretics for up to 24 hours following lumoxiti infusions. • an oral corticosteroid (e.g., 4 mg dexamethasone) is recommended to decrease nausea and vomiting. • maintain adequate oral fluid intake. 2.3 monitoring to assess safety manage adverse reactions by withholding and/or discontinuing lumoxiti as described below. identify capillary leak syndrome (cls) and hemolytic uremic syndrome (hus) based on clinical presentation (see table 1). table 1: monitoring for cls and hus cls hus monitoring parameter before every infusion, check: • weight • blood pressure before every infusion, check: • hemoglobin levels • platelet count • serum creatinine assessment • if weight has increased by 5.5 pounds (2.5 kg) or 5% or greater from day 1 of the cycle and the patient is hypotensive, promptly check for peripheral edema, hypoalbuminemia, and respiratory symptoms, including shortness of breath and cough. • if cls is suspected, check for a decrease in oxygen saturation and evidence of pulmonary edema and/or serosal effusions. if hus is suspected, promptly check blood ldh, indirect bilirubin, and blood smear schistocytes for evidence of hemolysis. adverse reactions graded by the national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03. capillary leak syndrome (cls) patients who experience grade 2 or higher cls should receive appropriate supportive measures, including treatment with oral or intravenous corticosteroids, with monitoring of weight, albumin levels, and blood pressure until resolution [see warnings and precautions (5.1) ] . table 2: cls grading and management guidance cls grade lumoxiti dosing grade 2 symptomatic; medical intervention indicated delay dosing until recovery of symptoms. grade 3 severe symptoms; medical intervention indicated discontinue lumoxiti. grade 4 life-threatening consequences; urgent intervention indicated per national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03. hemolytic uremic syndrome (hus) discontinue lumoxiti in patients with hus. treat with appropriate supportive measures and fluid replacement, with monitoring of blood chemistry, complete blood counts, and renal function until resolution [see warnings and precautions (5.2) ] . increased creatinine for patients with baseline serum creatinine within normal limits, delay dosing for grade 2 or higher creatinine increases (greater than 1.5‑times baseline or the upper limit of normal). resume lumoxiti upon recovery to grade 1 (1‑ to 1.5‑times baseline, or between the upper limit of normal and 1.5‑times the upper limit of normal). for patients with baseline serum creatinine of grades 1 or 2, delay dosing for creatinine increases to grade 3 or higher (greater than 3‑times baseline or the upper limit of normal). resume lumoxiti upon recovery to baseline grade or lower [see warnings and precautions (5.3) ] . 2.4 instructions for reconstitution, dilution, and administration lumoxiti must be reconstituted and diluted by a healthcare provider using aseptic technique. refer to the healthcare provider instructions for use for lumoxiti for full reconstitution, dilution, and administration information. step 1: calculate dose • calculate the dose (mg) and the number of lumoxiti vials (1 mg/vial) to be reconstituted. the final concentration of the reconstituted lumoxiti solution is 1 mg/ml. o do not round down for partial vials. • individualize dosing based on the patient's actual body weight prior to the first dose of the first treatment cycle. o a change in dose should only be made between cycles when a change in weight of greater than 10% is observed from the weight used to calculate the first dose of the first treatment cycle. no change in dose should be made during a particular cycle. step 2: reconstitution reconstitute lumoxiti vials with sterile water for injection, usp only. • reconstitute each lumoxiti (1 mg/vial) with 1.1 ml sterile water for injection, usp. the resulting 1 mg/ml solution allows a withdrawal volume of 1 ml. o direct the sterile water for injection, usp along the walls of the vial and not directly at the lyophilized cake or powder. o do not reconstitute lumoxiti vials with the iv solution stabilizer. • gently swirl the vial until completely dissolved. invert the vial to ensure all cake or powder in the vial is dissolved. do not shake. • visually inspect that the reconstituted solution is clear to slightly opalescent, colorless to slightly yellow, and free from visible particles. do not use if solution is cloudy, discolored, or contains any particles. • use reconstituted solution immediately. do not store reconstituted lumoxiti vials. see table 3 for storage times and conditions for the reconstituted solution. step 3: dilution add the iv solution stabilizer to the infusion bag prior to adding lumoxiti solution to the infusion bag. vial of iv solution stabilizer is packaged separately. • obtain a 50 ml 0.9% sodium chloride injection, usp infusion bag. • add 1 ml iv solution stabilizer to the infusion bag containing 50 ml 0.9% sodium chloride injection, usp. o only one vial of iv solution stabilizer should be used per administration of lumoxiti. o gently invert the bag to mix the solution. do not shake. • withdraw the required volume (calculated from step 1) of lumoxiti solution from the reconstituted vial(s). o inject lumoxiti into the infusion bag containing 50 ml 0.9% sodium chloride injection, usp and 1 ml iv solution stabilizer. o gently invert the bag to mix the solution. do not shake. • discard any partially used or empty vials of lumoxiti and iv solution stabilizer. • see table 3 for storage times and conditions for the diluted solution. step 4: administration instructions for intravenous infusion only. • administer the diluted solution intravenously over 30 minutes. • do not mix lumoxiti, or administer as an infusion with other medicinal products. • after the infusion, flush the intravenous administration line with of 0.9% sodium chloride injection, usp at the same rate as the infusion. this ensures that the full lumoxiti dose is delivered. table 3: storage times and conditions for reconstituted and diluted lumoxiti solution reconstituted solution diluted lumoxiti solution in infusion bag after dilution administration lumoxiti does not contain bacteriostatic preservatives. use reconstituted solution immediately. do not store reconstituted lumoxiti vials. use diluted solution immediately or after storage at room temperature (20°c to 25°c; 68°f to 77°f) for up to 4 hours or store refrigerated at 2°c to 8°c (36°f to 46°f) for up to 24 hours. protect from light. do not freeze. do not shake. if the diluted solution is refrigerated (2°c to 8°c; 36°f to 46°f), allow it to equilibrate at room temperature (20°c to 25°c; 68°f to 77°f) for no more than 4 hours prior to administration. administer diluted solution within 24 hours of reconstitution as a 30-minute infusion. protect from light.

ons, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. the safety data described in this section reflect exposure to lumoxiti in 80 patients with previously treated hcl in study 1053 [see clinical studies (14) ] . patients received lumoxiti 0.04 mg/kg as an intravenous infusion over 30 minutes on days 1, 3, and 5 of each 28‑day cycle for a maximum of 6 cycles or until disease progression or unacceptable toxicity. the median duration of treatment with lumoxiti was 5.7 months (range: 0.9 to 6.7), with a median of 6 treatment cycles started in each patient. the most common non-laboratory adverse reactions (≥ 20%) of any grade were infusion related reactions, edema, nausea, fatigue, headache, pyrexia, constipation, anemia, and diarrhea. the most common grade 3 or 4 adverse reactions (reported in at least ≥ 5% of patients) were hypertension, febrile neutropenia, and hus. the most common laboratory abnormalities (≥ 20%) of any grade were creatinine increased, alt increased, hypoalbuminemia, ast increased, hypocalcemia, hypophosphatemia, hemoglobin decreased, neutrophil count decreased, hyponatremia, blood bilirubin increased, hypokalemia, ggt increased, hypomagnesemia, platelet count decreased, hyperuricemia, and alkaline phosphate increased. adverse reactions resulting in permanent discontinuation of lumoxiti occurred in 15% (12/80) of patients. the most common adverse reaction leading to lumoxiti discontinuation was hus (5%). the most common adverse reaction resulting in dose delays, omissions, or interruptions was pyrexia (3.8%). tables 4 and 5 present the frequency category of adverse reactions and key laboratory abnormalities observed in patients with relapsed or refractory hcl treated with lumoxiti. table 4: adverse reactions per national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03. in ≥ 20% (all grades) of patients with hcl in study 1053 lumoxiti n=80 all grades (%) grade 3 (%) general disorders and administration site conditions edema peripheral 39 - fatigue 34 - pyrexia 31 1.3 gastrointestinal disorders nausea 35 2.5 constipation 23 - diarrhea 21 - injury, poisoning, and procedural complications infusion related reactions infusion related reactions: includes patients who were reported to have one or more infusion event that may be infusion-related on the day of study drug infusion. 50 3.8 nervous system disorders headache 33 - blood and lymphatic system disorders anemia 21 10 fluid retention occurred in 63% (50/80) of patients treated with lumoxiti in study 1053, including grade 3 in 1.3% (1/80) of patients. fluid retention included all preferred terms of edema peripheral (39%), face edema (14%), abdominal distension (13%), weight increased (8%), pleural effusion (6%), edema (5%), peripheral swelling (5%), localized edema (3.8%), ascites (1.3%), fluid overload (1.3%), fluid retention (1.3%), and pericardial effusion (1.3%). of the fifty patients with fluid retention, 29% of patients required diuretics. ocular adverse events occurred, including: blurred vision (9%), dry eye (8%), cataracts (5%), ocular discomfort and/or pain (4%), ocular swelling/periorbital edema (4%), conjunctivitis (1.3%), conjunctival hemorrhage (1.3%), and ocular discharge (1.3%). table 5: laboratory abnormalities per national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.03 and based on laboratory measurements worsening from baseline in ≥ 20% (all grades) reported in patients with hcl in study 1053 lumoxiti n=80 all grades (%) grade 3 (%) grade 4 (%) hematology hemoglobin decreased 43 15 - neutrophil count decreased 41 11 20 platelet count decreased 21 11 3.8 chemistry creatinine increased 96 2.5 - alt increased 65 3.8 - hypoalbuminemia 64 1.3 - ast increased 55 1.3 - hypocalcemia 54 - - hypophosphatemia 53 14 - hyponatremia 41 8.8 - blood bilirubin increased 30 1.3 - hypokalemia 25 1.3 1.3 ggt increased 25 - - hypomagnesemia 23 1.3 - hyperuricemia 21 - 2.5 alkaline phosphatase increased 20 - - alt=alanine aminotransferase; ast=aspartate aminotransferase; ggt=gamma glutamyl transferase 6.2 immunogenicity as with all therapeutic proteins, there is potential for immunogenicity. the detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. for these reasons, comparison of the incidence of antibodies to moxetumomab pasudotox-tdfk in the studies described below with the incidence of antibodies in other studies or to other products may be misleading. the immunogenicity of lumoxiti was evaluated using electrochemiluminescent (ecl)-based immunoassay to test for anti-moxetumomab pasudotox-tdfk antibodies (ada). for patients whose serum tested positive for ada, a cell-based assay was performed to detect neutralizing antibodies (nab). in study 1053, 59% (45/76) of patients tested positive for ada prior to any treatment with moxetumomab pasudotox-tdfk. seventy out of 80 subjects tested ada positive at any point during the study and were subsequently tested for nab. the results showed that 67 of 70 subjects were nab-positive. among these 67 patients who tested nab-positive, 99% (66/67) had ada specific to the pe38 binding domain, and 54% (36/67) also had ada specific to the cd22 binding domain. in 41 out of 73 patients who had baseline and post-baseline ada results, the median fold increase from baseline (cycle 1, day 1) in ada titer was 3.75- (range: 0 to 240), 54- (range: 0 to 2560), 120- (range: 0 to 1920), and 128- (range: 0 to 2560) fold at cycles 2, 3, 5, and end-of-treatment, respectively. patients who tested positive for ada had decreased systemic moxetumomab pasudotox-tdfk concentrations [see clinical pharmacology (12.3) ] .

respectively. 8.2 lactation risk summary no data are available regarding the presence of moxetumomab pasudotox-tdfk in human milk, the effects on the breastfed child, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for lumoxiti and any potential adverse effects on the breastfed child from lumoxiti or from the underlying maternal condition. 8.3 females and males of reproductive potential contraception females to avoid potential exposure to the fetus, women of reproductive potential should use effective contraception during treatment with lumoxiti and for at least 30 days after the last dose is received. verify the pregnancy status of females of reproductive potential prior to initiating lumoxiti. 8.4 pediatric use safety and effectiveness have not been established in pediatric patients. 8.5 geriatric use in the combined safety database of hcl patients treated with lumoxiti, 31% (40/129) of patients treated with lumoxiti were 65 years of age or older and 8% (10/129) were 75 years of age or older. exploratory analyses across this population suggest a higher incidence of adverse reactions leading to drug discontinuation (23% versus 7%) and renal toxicity (40% versus 20%) for patients 65 years of age or older as compared to those younger than 65 years. clinical studies of lumoxiti did not include sufficient numbers of subjects aged 65 and over to determine whether there were differences in efficacy between younger and older patients.

cells, and cd16+/cd56 natural killer cells and quantitative immunoglobulin (ig) a, g, and m levels were evaluated throughout the course of treatment. on day 8, median cell counts were reduced from baseline for the following populations: cd3+ t cells (-21%), cd4+ t cells (-20%), cd8+ t cells (-23%), and cd16+/cd56 natural killer cells (-47%). all monitored cell counts returned to, or were elevated above baseline levels on day 29 and thereafter. at baseline, the median iga, igg, and igm levels were 107 mg/dl (11-260), 834 mg/dl (387-3003), and 42 mg/dl (6-380), respectively, and remained generally unchanged at the end of treatment. 12.3 pharmacokinetics the pharmacokinetics (pk) of moxetumomab pasudotox-tdfk was studied in patients with hcl at doses ranging from 0.005 to 0.05 mg/kg (about 0.1 to 1.3 times the approved recommended dosage) administered intravenously over 30 minutes on days 1, 3, and 5 of a 28-day cycle. moxetumomab pasudotox-tdfk concentrations increased dose-proportionally over the studied dose range. the mean steady state moxetumomab pasudotox-tdfk exposures at the approved recommended dosages were 379 ng/ml (range: 20 to 862; sd: 262) for c max and 626 ng·hour/ml (range: 5 to 1960; sd: 610) for auc 0-last . no systemic accumulation of moxetumomab pasudotox-tdfk was observed. baseline cd19+ b cells were evaluated for association with the pk exposure and higher pk exposures were significantly associated with low baseline cd19+ counts (p < 0.001). distribution the population pk model estimated mean volume of distribution of moxetumomab pasudotox-tdfk was 6.5 l (sd 2.4). elimination the mean elimination half-life of moxetumomab pasudotox-tdfk was 1.4 hours (range: 0.8 to 1.8; sd: 0.35). the population pk model estimated mean systemic clearance of moxetumomab pasudotox-tdfk after the first dose of the first cycle was 25 l/hour (sd: 29.0) and after subsequent dosing was 4 l/hour (sd: 4.4). metabolism the metabolic pathway of moxetumomab pasudotox-tdfk in humans is unknown, however, other protein therapeutics generally undergo proteolytic degradation into small peptides and amino acids via catabolic pathways. specific populations no clinically significant differences in the pharmacokinetics of moxetumomab pasudotox-tdfk were observed for age (36 to 84 years), sex, race (white and non-white), body weight (42 to 152 kg), mild hepatic impairment (total bilirubin ≤ upper limit of normal [uln] and ast > uln, or total bilirubin > 1 to 1.5 times uln and any ast), mild renal impairment (clcr 60-89 ml/min; n=40), or moderate renal impairment (clcr 30-59 ml/min; n=4) based on population pk analysis. the pharmacokinetics of moxetumomab pasudotox-tdfk in patients with moderate to severe hepatic impairment (total bilirubin > 1.5 uln) or severe renal impairment (crcl ≤ 29 ml/min) is unknown. anti-product antibody formation affecting pk in patients who were ada-positive with high titers, the presence of ada post-baseline was associated with statistically significant (p < 0.05) lower pk exposure (c max ) at later cycles (cycle 3 and beyond).

ination half-life of moxetumomab pasudotox-tdfk was 1.4 hours (range: 0.8 to 1.8; sd: 0.35). the population pk model estimated mean systemic clearance of moxetumomab pasudotox-tdfk after the first dose of the first cycle was 25 l/hour (sd: 29.0) and after subsequent dosing was 4 l/hour (sd: 4.4). metabolism the metabolic pathway of moxetumomab pasudotox-tdfk in humans is unknown, however, other protein therapeutics generally undergo proteolytic degradation into small peptides and amino acids via catabolic pathways. specific populations no clinically significant differences in the pharmacokinetics of moxetumomab pasudotox-tdfk were observed for age (36 to 84 years), sex, race (white and non-white), body weight (42 to 152 kg), mild hepatic impairment (total bilirubin ≤ upper limit of normal [uln] and ast > uln, or total bilirubin > 1 to 1.5 times uln and any ast), mild renal impairment (clcr 60-89 ml/min; n=40), or moderate renal impairment (clcr 30-59 ml/min; n=4) based on population pk analysis. the pharmacokinetics of moxetumomab pasudotox-tdfk in patients with moderate to severe hepatic impairment (total bilirubin > 1.5 uln) or severe renal impairment (crcl ≤ 29 ml/min) is unknown. anti-product antibody formation affecting pk in patients who were ada-positive with high titers, the presence of ada post-baseline was associated with statistically significant (p < 0.05) lower pk exposure (c max ) at later cycles (cycle 3 and beyond).

rituximab. the most common other prior treatment regimens were rituximab monotherapy (51%), interferon-alpha (25%), and a braf inhibitor (18%). at baseline, 33% (26/80) of patients had low hemoglobin (< 10 g/dl), 68% (54/80) of patients had neutropenia (< 1000/mm 3 ), and 84% (67/80) patients had baseline platelet counts < 100,000/mm 3 . about 35% of patients had enlarged spleens (≥ 14 cm, assessed by bicr) at baseline. patients received lumoxiti 0.04 mg/kg as an intravenous infusion over 30 minutes on days 1, 3, and 5 of each 28‑day cycle for a maximum of 6 cycles or until documentation of complete response (cr), disease progression, or unacceptable toxicity. the median duration of follow-up was 16.7 months (range: 2 to 49). an independent review committee (irc) performed efficacy evaluations using blood, bone marrow, and imaging criteria adapted from previous hcl studies and consensus guidelines. efficacy of lumoxiti in hcl was evaluated by the irc-assessed rate of durable cr, as confirmed by maintenance of hematologic remission (hemoglobin ≥ 11 g/dl, neutrophils ≥ 1500/mm 3 , and platelets ≥ 100,000/mm 3 without transfusions or growth factor for at least 4 weeks) more than 180 days after irc-assessed cr. the irc-assessed durable cr rate was 30% (24/80 patients; 95% ci: 20, 41). additional efficacy outcome measures included overall response rate (orr), cr, and duration of response (see table 6). table 6: additional efficacy results in patients with hcl in study 1053 independent review committee (irc) assessed n=80 overall response rate overall response rate orr defined as best overall response of cr or pr. (%) [95% ci] 75 [64, 84] complete response cr defined as clearing of the bone marrow of hairy cells by routine hematoxylin & eosin stain, radiologic resolution of pre-existing lymphadenopathy and/or organomegaly, and hematologic remission. (%) [95% ci] 41 [30, 53] partial response pr defined as ≥ 50% decrease or normalization (< 500/mm 3 ) in peripheral blood lymphocyte count, reduction of pre-existing lymphadenopathy and/or organomegaly, and hematologic remission. (%) [95% ci] 34 [24, 45] duration of response median in months [range] nr [0+ to 43+] duration of cr median in months [range] nr [0+ to 40+] ci=confidence interval; nr=not reached; + indicates censored observations the median time to orr and cr was 5.7 months (range: 1.8 to 12.9) and 5.9 months (range 1.8 to 13.2), respectively. sixty-four patients (80%) had normalization of hematologic parameters and achieved hematologic remission, with a median time to hematologic remission of 1.1 months (range: 0.2 to 13) and with a median duration of hematologic remission not reached (range: 0.3 to 48.2+).

se reactions (6.1) ] . infusion related reactions advise patients to contact their healthcare provider immediately for signs or symptoms of infusion related reactions [see warnings and precautions (5.4) ] . electrolyte abnormalities advise patients to report symptoms of electrolyte abnormalities (e.g., muscle cramping, paresthesias, irregular or fast heartbeat, nausea, seizures) to their healthcare provider immediately [see warnings and precautions (5.5) ] . distributed by: astrazeneca pharmaceuticals lp, wilmington, de 19850 manufactured by: astrazeneca ab, södertälje, sweden se-15185 u.s. license no. 2059 lumoxiti is a trademark of the astrazeneca group of companies. © astrazeneca 2021